Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Allergan Issues Voluntary Nationwide Recall in the U.S. of Specific Lots of REFRESH® Lacri-Lube®, REFRESH P.M. ®, FML® (fluorometholone ophthalmic ointment) 0.1%, and Blephamide® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% for Particulate Matter

      Allergan plc

      News provided by

      Allergan plc

      Aug 24, 2015, 08:35 ET

      Share this article

      Share this article


      DUBLIN, Aug. 24, 2015 /PRNewswire/ -- Allergan plc, today announced that it is conducting a voluntary recall down to consumer level of specific lots of its REFRESH® Lacri-Lube® 3.5g and 7g  for dry eye, REFRESH P.M.® 3.5g for dry eye, FML® (fluorometholone ophthalmic ointment) 0.1% (sterile ophthalmic ointment topical anti-inflammatory agent for ophthalmic use, 3.5g), and Blephamide® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile topical ophthalmic ointment combining an antibacterial and a corticosteroid, 3.5g. 

      Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

      Allergan chose to initiate this recall based on a small number of customer complaints which reported a small black particle at the time of use. This black particle, which is part of the cap, can be created by the action from unscrewing the cap of the aluminum tube, and potentially introduced into the product. Reported adverse events include Foreign Body in Eye (12), Eye Irritation (2), Ocular Discomfort (2), Product Contamination (2), Superficial Injury of Eye (2), Eye Pain (1), Eye Swelling (1) and Vision Blurred (1).

      Specific lots are being voluntarily recalled in the interest of patient safety. If the particle gets into the eye, potential adverse events may include eye pain, eye swelling, ocular discomfort or eye irritation. Please contact your physician or healthcare provider if you have any of these symptoms when using these products. The lot number and expiration date may be found on the bottom flap of the carton with the safety seal and on the crimp seal of the product tube.

      Specific information on product and lots that are being voluntarily recalled are below

      NDC

      Description

      Lot Number

      Expiration Date

      0023-0312-04

      REFRESH® Lacri-Lube® 3.5 g

      84746

      Apr-17

      0023-0312-04

      REFRESH® Lacri-Lube® 3.5 g

      84987

      May-17

      0023-0312-04

      REFRESH® Lacri-Lube® 3.5 g

      85087

      May-17

      0023-0312-04

      REFRESH® Lacri-Lube® 3.5 g

      85359

      Jun-17

      0023-0312-04

      REFRESH® Lacri-Lube® 3.5 g

      85721

      Jul-17

      0023-0312-04

      REFRESH® Lacri-Lube® 3.5 g

      86045

      Aug-17

      0023-0312-04

      REFRESH® Lacri-Lube® 3.5 g

      86406

      Sep-17

      0023-0312-04

      REFRESH® Lacri-Lube® 3.5 g

      86594

      Oct-17

      0023-0312-04

      REFRESH® Lacri-Lube® 3.5 g

      87021

      Nov-17

      0023-0312-07

      REFRESH® Lacri-Lube® 7g

      86470

      Sep-17

      0023-0312-07

      REFRESH® Lacri-Lube® 7g

      86829

      Oct-17

      0023-0312-07

      REFRESH® Lacri-Lube® 7g

      87105

      Nov-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85165

      May-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85228

      May-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85244

      Jun-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85351

      Jun-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85374

      Jun-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85397

      Jun-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85561

      Jul-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85676

      Jul-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85694

      Jul-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85834

      Aug-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85977

      Aug-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85985

      Aug-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86073

      Aug-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      85599

      Sep-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86290

      Sep-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86325

      Sep-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86411

      Sep-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86427

      Sep-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86506

      Sep-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86515

      Sep-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86517

      Sep-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86746

      Oct-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86792

      Oct-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86789

      Oct-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86809

      Oct-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86822

      Oct-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86822A

      Oct-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      86932

      Nov-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      87100

      Nov-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      87068

      Nov-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      87156

      Dec-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      87261

      Dec-17

      0023-0240-04

      REFRESH P.M.® 3.5 g

      87493

      Jan-18

      0023-0240-04

      REFRESH P.M.® 3.5 g

      87494

      Feb-18

      0023-0240-04

      REFRESH P.M.® 3.5 g

      87731

      Feb-18

      0023-0240-04

      REFRESH P.M.® 3.5 g  (Professional
      Sample Pack)

      85165

      May-17

      0023-0240-04

      REFRESH P.M.® 3.5 g (Professional
      Sample Pack)

      86789

      Oct-17

      0023-0316-04

      FML® (fluorometholone ophthalmic
      ointment) 0.1%, 3.5 g

      86258

      Sep-17

      0023-0316-04

      FML® (fluorometholone ophthalmic
      ointment) 0.1%, 3.5 g

      87189

      Dec-17

      0023-0316-04

      FML® (fluorometholone ophthalmic
      ointment) 0.1%, 3.5 g

      87514

      Feb-18

      0023-0313-04

      Blephamide® (sulfacetamide sodium and
      prednisolone acetate ophthalmic ointment, USP) 10%/0.2%, 3.5 g

      86430

      Sep-17

      0023-0313-04

      Blephamide® (sulfacetamide sodium and
      prednisolone acetate ophthalmic ointment, USP) 10%/0.2%, 3.5 g

      87806

      Feb-18

      0023-0313-04

      Blephamide® (sulfacetamide sodium and
      prednisolone acetate ophthalmic ointment, USP) 10%/0.2%, 3.5 g

      88147

      Mar-18

      Allergan has informed the U.S. Food and Drug Administration of this voluntary recall. The recall only applies to specific lots of the REFRESH® Lacri-Lube®, REFRESH P.M. ®, FML® (fluorometholone ophthalmic ointment) 0.1%, Blephamide® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2%. This recall does not affect any other REFRESH or Allergan product.  

      Allergan is contacting retailers and wholesalers who have been shipped affected product lots to initiate the recall and is informing them of the steps needed to return affected product.

      The company is asking consumers who currently have product from any of the affected  lots of REFRESH® Lacri-Lube®, REFRESH P.M. ®, FML® (fluorometholone ophthalmic ointment) 0.1% , Blephamide® (sulfacetamide sodium or prednisolone acetate ophthalmic ointment, USP) 10%/0.2%, to stop using the product and return it to Allergan.

      If there are questions or if assistance is required in response to this recall, please use the contact information below.

      CONTACT INFORMATION

      Product Returns

      Contact GENCO at:

      877-674-2087

      7 am to 5 pm CST

      Credit/Reimbursements

      Contact Allergan at:

      1-800-811-4148

      7am to 5pm PST

      Allergan

      Medical Inquiries:

      1-800-433-8871 option 2 8am - 5pm PST

      Adverse Events/Product Complaints:

      1-800-624-4261 Option 3 (8am – 5pm CST

      FDA contact information for reporting adverse events/quality complaints:

      Online at www.fda.gov/medwatch/report.htm or call FDA at 1-800-FDA-1088

      Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to the use of this product.

      CONTACTS:

      Investors:
      Lisa DeFrancesco
      (862) 261-7152

      Media:
      Mark Marmur
      (973) 906-1526

      SOURCE Allergan plc

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.